Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Research Report 2024(Status and Outlook)
Report Overview:
Inactivated vaccines for Swine Mycoplasma pneumonia are also available. They are made by using inactivated or killed strains of the bacteria to stimulate an immune response in pigs without causing disease.
The Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size was estimated at USD 383.81 million in 2023 and is projected to reach USD 589.03 million by 2029, exhibiting a CAGR of 7.40% during the forecast period.
This report provides a deep insight into the global Inactivated Vaccine for Swine Mycoplasma Pneumonia market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Inactivated Vaccine for Swine Mycoplasma Pneumonia market in any manner.
Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Zoetis
Boehringer Ingelheim
Jinhe Biotechnology
Merck
HIPRA
Ceva Santй Animale
Harbin Pharmaceutical Group
Pulike Biotech
Qilu Animal Health Products
Wuhan Keqian Biology
Market Segmentation (by Type)
Single Vaccine
Dual Vaccine
Market Segmentation (by Application)
Piglets
Adult Pigs
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Inactivated Vaccine for Swine Mycoplasma Pneumonia Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Inactivated vaccines for Swine Mycoplasma pneumonia are also available. They are made by using inactivated or killed strains of the bacteria to stimulate an immune response in pigs without causing disease.
The Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size was estimated at USD 383.81 million in 2023 and is projected to reach USD 589.03 million by 2029, exhibiting a CAGR of 7.40% during the forecast period.
This report provides a deep insight into the global Inactivated Vaccine for Swine Mycoplasma Pneumonia market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Inactivated Vaccine for Swine Mycoplasma Pneumonia market in any manner.
Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Zoetis
Boehringer Ingelheim
Jinhe Biotechnology
Merck
HIPRA
Ceva Santй Animale
Harbin Pharmaceutical Group
Pulike Biotech
Qilu Animal Health Products
Wuhan Keqian Biology
Market Segmentation (by Type)
Single Vaccine
Dual Vaccine
Market Segmentation (by Application)
Piglets
Adult Pigs
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Inactivated Vaccine for Swine Mycoplasma Pneumonia Market
- Overview of the regional outlook of the Inactivated Vaccine for Swine Mycoplasma Pneumonia Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Inactivated Vaccine for Swine Mycoplasma Pneumonia Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Inactivated Vaccine for Swine Mycoplasma Pneumonia
1.2 Key Market Segments
1.2.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Segment by Type
1.2.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 INACTIVATED VACCINE FOR SWINE MYCOPLASMA PNEUMONIA MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 INACTIVATED VACCINE FOR SWINE MYCOPLASMA PNEUMONIA MARKET COMPETITIVE LANDSCAPE
3.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Manufacturers (2019-2024)
3.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Market Share by Manufacturers (2019-2024)
3.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Sites, Area Served, Product Type
3.6 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Competitive Situation and Trends
3.6.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Concentration Rate
3.6.2 Global 5 and 10 Largest Inactivated Vaccine for Swine Mycoplasma Pneumonia Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 INACTIVATED VACCINE FOR SWINE MYCOPLASMA PNEUMONIA INDUSTRY CHAIN ANALYSIS
4.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF INACTIVATED VACCINE FOR SWINE MYCOPLASMA PNEUMONIA MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 INACTIVATED VACCINE FOR SWINE MYCOPLASMA PNEUMONIA MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Type (2019-2024)
6.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Market Share by Type (2019-2024)
6.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Type (2019-2024)
7 INACTIVATED VACCINE FOR SWINE MYCOPLASMA PNEUMONIA MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Sales by Application (2019-2024)
7.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size (M USD) by Application (2019-2024)
7.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Growth Rate by Application (2019-2024)
8 INACTIVATED VACCINE FOR SWINE MYCOPLASMA PNEUMONIA MARKET SEGMENTATION BY REGION
8.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region
8.1.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region
8.1.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Region
8.2 North America
8.2.1 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Zoetis
9.1.1 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.1.2 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.1.3 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.1.4 Zoetis Business Overview
9.1.5 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia SWOT Analysis
9.1.6 Zoetis Recent Developments
9.2 Boehringer Ingelheim
9.2.1 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.2.2 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.2.3 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.2.4 Boehringer Ingelheim Business Overview
9.2.5 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia SWOT Analysis
9.2.6 Boehringer Ingelheim Recent Developments
9.3 Jinhe Biotechnology
9.3.1 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.3.2 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.3.3 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.3.4 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia SWOT Analysis
9.3.5 Jinhe Biotechnology Business Overview
9.3.6 Jinhe Biotechnology Recent Developments
9.4 Merck
9.4.1 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.4.2 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.4.3 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.4.4 Merck Business Overview
9.4.5 Merck Recent Developments
9.5 HIPRA
9.5.1 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.5.2 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.5.3 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.5.4 HIPRA Business Overview
9.5.5 HIPRA Recent Developments
9.6 Ceva Santй Animale
9.6.1 Ceva Santй Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.6.2 Ceva Santй Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.6.3 Ceva Santй Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.6.4 Ceva Santй Animale Business Overview
9.6.5 Ceva Santй Animale Recent Developments
9.7 Harbin Pharmaceutical Group
9.7.1 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.7.2 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.7.3 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.7.4 Harbin Pharmaceutical Group Business Overview
9.7.5 Harbin Pharmaceutical Group Recent Developments
9.8 Pulike Biotech
9.8.1 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.8.2 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.8.3 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.8.4 Pulike Biotech Business Overview
9.8.5 Pulike Biotech Recent Developments
9.9 Qilu Animal Health Products
9.9.1 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.9.2 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.9.3 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.9.4 Qilu Animal Health Products Business Overview
9.9.5 Qilu Animal Health Products Recent Developments
9.10 Wuhan Keqian Biology
9.10.1 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.10.2 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.10.3 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.10.4 Wuhan Keqian Biology Business Overview
9.10.5 Wuhan Keqian Biology Recent Developments
10 INACTIVATED VACCINE FOR SWINE MYCOPLASMA PNEUMONIA MARKET FORECAST BY REGION
10.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast
10.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Country
10.2.3 Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Region
10.2.4 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type (2025-2030)
11.1.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type (2025-2030)
11.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast by Application (2025-2030)
11.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons) Forecast by Application
11.2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Inactivated Vaccine for Swine Mycoplasma Pneumonia
1.2 Key Market Segments
1.2.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Segment by Type
1.2.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 INACTIVATED VACCINE FOR SWINE MYCOPLASMA PNEUMONIA MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 INACTIVATED VACCINE FOR SWINE MYCOPLASMA PNEUMONIA MARKET COMPETITIVE LANDSCAPE
3.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Manufacturers (2019-2024)
3.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Market Share by Manufacturers (2019-2024)
3.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Sites, Area Served, Product Type
3.6 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Competitive Situation and Trends
3.6.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Concentration Rate
3.6.2 Global 5 and 10 Largest Inactivated Vaccine for Swine Mycoplasma Pneumonia Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 INACTIVATED VACCINE FOR SWINE MYCOPLASMA PNEUMONIA INDUSTRY CHAIN ANALYSIS
4.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF INACTIVATED VACCINE FOR SWINE MYCOPLASMA PNEUMONIA MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 INACTIVATED VACCINE FOR SWINE MYCOPLASMA PNEUMONIA MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Type (2019-2024)
6.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Market Share by Type (2019-2024)
6.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Type (2019-2024)
7 INACTIVATED VACCINE FOR SWINE MYCOPLASMA PNEUMONIA MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Sales by Application (2019-2024)
7.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size (M USD) by Application (2019-2024)
7.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Growth Rate by Application (2019-2024)
8 INACTIVATED VACCINE FOR SWINE MYCOPLASMA PNEUMONIA MARKET SEGMENTATION BY REGION
8.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region
8.1.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region
8.1.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Region
8.2 North America
8.2.1 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Zoetis
9.1.1 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.1.2 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.1.3 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.1.4 Zoetis Business Overview
9.1.5 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia SWOT Analysis
9.1.6 Zoetis Recent Developments
9.2 Boehringer Ingelheim
9.2.1 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.2.2 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.2.3 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.2.4 Boehringer Ingelheim Business Overview
9.2.5 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia SWOT Analysis
9.2.6 Boehringer Ingelheim Recent Developments
9.3 Jinhe Biotechnology
9.3.1 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.3.2 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.3.3 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.3.4 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia SWOT Analysis
9.3.5 Jinhe Biotechnology Business Overview
9.3.6 Jinhe Biotechnology Recent Developments
9.4 Merck
9.4.1 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.4.2 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.4.3 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.4.4 Merck Business Overview
9.4.5 Merck Recent Developments
9.5 HIPRA
9.5.1 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.5.2 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.5.3 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.5.4 HIPRA Business Overview
9.5.5 HIPRA Recent Developments
9.6 Ceva Santй Animale
9.6.1 Ceva Santй Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.6.2 Ceva Santй Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.6.3 Ceva Santй Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.6.4 Ceva Santй Animale Business Overview
9.6.5 Ceva Santй Animale Recent Developments
9.7 Harbin Pharmaceutical Group
9.7.1 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.7.2 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.7.3 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.7.4 Harbin Pharmaceutical Group Business Overview
9.7.5 Harbin Pharmaceutical Group Recent Developments
9.8 Pulike Biotech
9.8.1 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.8.2 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.8.3 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.8.4 Pulike Biotech Business Overview
9.8.5 Pulike Biotech Recent Developments
9.9 Qilu Animal Health Products
9.9.1 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.9.2 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.9.3 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.9.4 Qilu Animal Health Products Business Overview
9.9.5 Qilu Animal Health Products Recent Developments
9.10 Wuhan Keqian Biology
9.10.1 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
9.10.2 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
9.10.3 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
9.10.4 Wuhan Keqian Biology Business Overview
9.10.5 Wuhan Keqian Biology Recent Developments
10 INACTIVATED VACCINE FOR SWINE MYCOPLASMA PNEUMONIA MARKET FORECAST BY REGION
10.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast
10.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Country
10.2.3 Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Region
10.2.4 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type (2025-2030)
11.1.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type (2025-2030)
11.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast by Application (2025-2030)
11.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons) Forecast by Application
11.2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Comparison by Region (M USD)
Table 5. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Vaccine for Swine Mycoplasma Pneumonia as of 2022)
Table 10. Global Market Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Sites and Area Served
Table 12. Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Type
Table 13. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Inactivated Vaccine for Swine Mycoplasma Pneumonia
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Challenges
Table 22. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Type (Kilotons)
Table 23. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Type (M USD)
Table 24. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons) by Type (2019-2024)
Table 25. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Type (2019-2024)
Table 26. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size (M USD) by Type (2019-2024)
Table 27. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Share by Type (2019-2024)
Table 28. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (USD/Ton) by Type (2019-2024)
Table 29. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons) by Application
Table 30. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Application
Table 31. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Application (2019-2024)
Table 33. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Application (2019-2024) & (M USD)
Table 34. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Application (2019-2024)
Table 35. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Growth Rate by Application (2019-2024)
Table 36. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Region (2019-2024)
Table 38. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region (2019-2024) & (Kilotons)
Table 43. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 44. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 45. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Zoetis Business Overview
Table 47. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia SWOT Analysis
Table 48. Zoetis Recent Developments
Table 49. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 50. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 51. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Boehringer Ingelheim Business Overview
Table 53. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia SWOT Analysis
Table 54. Boehringer Ingelheim Recent Developments
Table 55. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 56. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 57. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia SWOT Analysis
Table 59. Jinhe Biotechnology Business Overview
Table 60. Jinhe Biotechnology Recent Developments
Table 61. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 62. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 63. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Merck Business Overview
Table 65. Merck Recent Developments
Table 66. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 67. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 68. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. HIPRA Business Overview
Table 70. HIPRA Recent Developments
Table 71. Ceva Santй Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 72. Ceva Santй Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 73. Ceva Santй Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Ceva Santй Animale Business Overview
Table 75. Ceva Santй Animale Recent Developments
Table 76. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 77. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 78. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Harbin Pharmaceutical Group Business Overview
Table 80. Harbin Pharmaceutical Group Recent Developments
Table 81. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 82. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 83. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Pulike Biotech Business Overview
Table 85. Pulike Biotech Recent Developments
Table 86. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 87. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 88. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Qilu Animal Health Products Business Overview
Table 90. Qilu Animal Health Products Recent Developments
Table 91. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 92. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 93. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Wuhan Keqian Biology Business Overview
Table 95. Wuhan Keqian Biology Recent Developments
Table 96. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Region (2025-2030) & (Kilotons)
Table 97. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Region (2025-2030) & (M USD)
Table 98. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Country (2025-2030) & (Kilotons)
Table 99. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Country (2025-2030) & (M USD)
Table 100. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Country (2025-2030) & (Kilotons)
Table 101. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Country (2025-2030) & (M USD)
Table 102. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Region (2025-2030) & (Kilotons)
Table 103. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Region (2025-2030) & (M USD)
Table 104. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Country (2025-2030) & (Kilotons)
Table 105. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Country (2025-2030) & (M USD)
Table 106. Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Forecast by Country (2025-2030) & (Units)
Table 107. Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Country (2025-2030) & (M USD)
Table 108. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Type (2025-2030) & (Kilotons)
Table 109. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Type (2025-2030) & (M USD)
Table 110. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price Forecast by Type (2025-2030) & (USD/Ton)
Table 111. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons) Forecast by Application (2025-2030)
Table 112. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Comparison by Region (M USD)
Table 5. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Vaccine for Swine Mycoplasma Pneumonia as of 2022)
Table 10. Global Market Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Sites and Area Served
Table 12. Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Type
Table 13. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Inactivated Vaccine for Swine Mycoplasma Pneumonia
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Challenges
Table 22. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Type (Kilotons)
Table 23. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Type (M USD)
Table 24. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons) by Type (2019-2024)
Table 25. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Type (2019-2024)
Table 26. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size (M USD) by Type (2019-2024)
Table 27. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Share by Type (2019-2024)
Table 28. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (USD/Ton) by Type (2019-2024)
Table 29. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons) by Application
Table 30. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Application
Table 31. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Application (2019-2024)
Table 33. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Application (2019-2024) & (M USD)
Table 34. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Application (2019-2024)
Table 35. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Growth Rate by Application (2019-2024)
Table 36. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Region (2019-2024)
Table 38. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region (2019-2024) & (Kilotons)
Table 43. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 44. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 45. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Zoetis Business Overview
Table 47. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia SWOT Analysis
Table 48. Zoetis Recent Developments
Table 49. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 50. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 51. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. Boehringer Ingelheim Business Overview
Table 53. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia SWOT Analysis
Table 54. Boehringer Ingelheim Recent Developments
Table 55. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 56. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 57. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia SWOT Analysis
Table 59. Jinhe Biotechnology Business Overview
Table 60. Jinhe Biotechnology Recent Developments
Table 61. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 62. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 63. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Merck Business Overview
Table 65. Merck Recent Developments
Table 66. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 67. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 68. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. HIPRA Business Overview
Table 70. HIPRA Recent Developments
Table 71. Ceva Santй Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 72. Ceva Santй Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 73. Ceva Santй Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Ceva Santй Animale Business Overview
Table 75. Ceva Santй Animale Recent Developments
Table 76. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 77. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 78. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Harbin Pharmaceutical Group Business Overview
Table 80. Harbin Pharmaceutical Group Recent Developments
Table 81. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 82. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 83. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Pulike Biotech Business Overview
Table 85. Pulike Biotech Recent Developments
Table 86. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 87. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 88. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Qilu Animal Health Products Business Overview
Table 90. Qilu Animal Health Products Recent Developments
Table 91. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 92. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 93. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 94. Wuhan Keqian Biology Business Overview
Table 95. Wuhan Keqian Biology Recent Developments
Table 96. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Region (2025-2030) & (Kilotons)
Table 97. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Region (2025-2030) & (M USD)
Table 98. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Country (2025-2030) & (Kilotons)
Table 99. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Country (2025-2030) & (M USD)
Table 100. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Country (2025-2030) & (Kilotons)
Table 101. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Country (2025-2030) & (M USD)
Table 102. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Region (2025-2030) & (Kilotons)
Table 103. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Region (2025-2030) & (M USD)
Table 104. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Country (2025-2030) & (Kilotons)
Table 105. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Country (2025-2030) & (M USD)
Table 106. Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Forecast by Country (2025-2030) & (Units)
Table 107. Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Country (2025-2030) & (M USD)
Table 108. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Type (2025-2030) & (Kilotons)
Table 109. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Type (2025-2030) & (M USD)
Table 110. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price Forecast by Type (2025-2030) & (USD/Ton)
Table 111. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons) Forecast by Application (2025-2030)
Table 112. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Inactivated Vaccine for Swine Mycoplasma Pneumonia
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size (M USD), 2019-2030
Figure 5. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size (M USD) (2019-2030)
Figure 6. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Country (M USD)
Figure 11. Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Share by Manufacturers in 2023
Figure 12. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Share by Manufacturers in 2023
Figure 13. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Type
Figure 18. Sales Market Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type (2019-2024)
Figure 19. Sales Market Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type in 2023
Figure 20. Market Size Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type (2019-2024)
Figure 21. Market Size Market Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Application
Figure 24. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Application (2019-2024)
Figure 25. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Application in 2023
Figure 26. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Application (2019-2024)
Figure 27. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Application in 2023
Figure 28. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Growth Rate by Application (2019-2024)
Figure 29. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Region (2019-2024)
Figure 30. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Country in 2023
Figure 32. U.S. Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Country in 2023
Figure 37. Germany Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Region in 2023
Figure 44. China Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (Kilotons)
Figure 50. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Country in 2023
Figure 51. Brazil Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share Forecast by Type (2025-2030)
Figure 65. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Application (2025-2030)
Figure 66. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Inactivated Vaccine for Swine Mycoplasma Pneumonia
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size (M USD), 2019-2030
Figure 5. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size (M USD) (2019-2030)
Figure 6. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Country (M USD)
Figure 11. Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Share by Manufacturers in 2023
Figure 12. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Share by Manufacturers in 2023
Figure 13. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Type
Figure 18. Sales Market Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type (2019-2024)
Figure 19. Sales Market Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type in 2023
Figure 20. Market Size Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type (2019-2024)
Figure 21. Market Size Market Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Application
Figure 24. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Application (2019-2024)
Figure 25. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Application in 2023
Figure 26. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Application (2019-2024)
Figure 27. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Application in 2023
Figure 28. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Growth Rate by Application (2019-2024)
Figure 29. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Region (2019-2024)
Figure 30. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Country in 2023
Figure 32. U.S. Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Country in 2023
Figure 37. Germany Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Region in 2023
Figure 44. China Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (Kilotons)
Figure 50. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Country in 2023
Figure 51. Brazil Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share Forecast by Type (2025-2030)
Figure 65. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Application (2025-2030)
Figure 66. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share Forecast by Application (2025-2030)
